Comments on: Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial  https://thegbm.com/novartis-oral-fabhalta-iptacopan-sustained-clinically-meaningful-results-at-one-year-in-phase-iii-c3-glomerulopathy-c3g-trial/ Business news, opinion, reviews, interviews Sat, 26 Oct 2024 23:50:00 +0000 hourly 1 https://wordpress.org/?v=6.6.2